IT SHOULD BE NOTED THAT THE USE OF THE PRODUCT IS NOT RECOMMENDED

NEO BORICILLIN THROAT PAIN

active ingredients

NEO BOROCILLINA GOLA DOLORE 0.25% collutory and NEO BOROCILLINA GOLA DOLORE 0.25% oral mucosa spray (all presentations) 100 ml of solution contain: Active ingredient: Flurbiprofen 0.25 g. Excipients with known effects: ethanol 9,60 g; liquid sorbitol (not crystallized) 7,00 g; methyl-p-hydroxybenzoate 0.10 g; propile- p-hydroxybenzoate 0.02 g; glycerol 10 g; sodium 6,8 mg. NEO BOROCILLINA GOLA DOLORE 0.25% oral mucosa spray taste orange and honey and NEO BOROCILLINA GOLA DOLORE 0.25% oral mucosa spray lemon and honey also contain the excipient with known yellow sunset effect (E110): 100 ml of solution contain: yellow sunset (E110): 0.014 g (presentation 0.25% spray for oral mucosa taste orange and honey); 0.006 g (presentation 0.25% lemon and honey taste oral mucosa spray) For the full list of excipients, see paragraph 6.1 NEO BOROCILLINA GOLA DOLORE 8,75 mg tablets (all presentations) A pastel contains: Active ingredient: Flurbiprofen 8.75 mg. Excipients with known effects: glycerol 20 mg; isomalto 931,45 mg (orange and honey taste); 936.45 mg ( lemon and honey taste) ; 913.25 mg (meta taste). For the full list of excipients, see paragraph 6.1

Excellent

Mouthwashing and spray for oral mucosa mint taste Glicerolo, ethyl alcohol (ethanol 96%), sorbitol liquid (not crystallized), castor oil hydrogenated 40 polyxyethylene, sodium hydroxide, saccharin soda, , ethyl-p-hydroxybenzoate, propile-p-hydroxybenzoate, essential oil mint, blue patent V (E 131), citric acid, purified water. Lemon and honey taste oral mucosal spray Glycerol, ethyl alcohol (ethanol 96%), sorbitol liquid (not crystallized), castor oil hydrogenated 40 polyxyethylene, sodium hydroxide, saccharin soda, , methyl -p-hydroxybenzoate, propile-p-hydroxybenzoate, honey aroma, lemon aroma, mint aroma, yellow sunset (E110)), citric acid, purified water. Orange and honey taste oral mucosal spray Glicerolo, ethyl alcohol (ethanol 96%), sorbitol liquid (not crystallized), castor oil hydrogenated 40 polyxyethylene, sodium hydroxide, saccharin soda, , methyl -p-hydroxybenzoate, propile-p-hydroxybenzoate, honey aroma, orange aroma, mint aroma, yellow sunset (E110), citric acid, purified water. Peppers without sugar taste mint Glicerolo dibeenate, potassium acesulfame, balsamic mint aroma, isomalto, copovidone. Meals without sugar lemon taste and honey Glicerolo dibeenate, potassium acesulfame, honey lemon aroma, isomalto, copovidone. Pastiglie without sugar taste orange and honey Glicerolo dibeenate, potassium acesulfame, honey orange aroma, isomalto, copovidone.

Therapeutic indications

NEO BOROCILLINA GOLA DOLORE collutorio / NEO BOROCILLINA GOLA DOLORE oral mucosa spray is used in the symptomatic treatment of irritative-inflammatory states also associated with pain of the oropharyngeal cable (e.g. gums, stomatitis, pharyngitis), also as a result of conservative or extractive dental therapy. NEO BOROCILLINA GOLA DOLORE tablets is used in the symptomatic treatment of irritative-inflammatory states also associated with pain of the oropharyngeal cable (e.g. gums, stomatitis, pharyngitis).

Contraindications

Flurbiprofen is contraindicated in patients with hypersensitivity (asthma, bronchospasm, hives or allergic type) towards flurbiprofen or any of the excipients, and towards acetilsalicylic acid or other non-steroidal anti-inflammatory drugs (FANS). Third quarter of pregnancy. Flurbiprofene administration is not recommended in nursing mothers. Do not use in patients who are suffering from peptic ulcer or have been affected in the past. Do not administer pads to children under the age of 12 years.

Dosage

Collumination The recommended dose is 2-3 shawls or gargarisms per day with 10 ml of mouthwashing (using the appropriate scoop), diluted in half a glass of water or pure. Oral Mucosa Spray The recommended dose is 2 sprays 3 times a day directly addressed to the interested party; each spray dispenses 0.2 ml of solution, equivalent to 0.5 mg of active ingredient. Meals Adults and boys over 12 years: 1 batter to dissolve slowly in the mouth every 3-6 hours, according to need. Do not exceed the dose of 8 pills in 24 hours. Do not administer children under the age of 12. Changes in posology are not necessary for older people.

Conservation

Collutory and oral mucosa spray: No special condition of conservation. Meals: Store at a temperature not exceeding 25°C.

Warnings

When using the medicine in its various pharmaceutical forms, the possible swallowing does not, in itself, entail any harm to the patient, since such doses are widely lower than those commonly used in treatment with systemic flurbiprofen. In patients with kidney, heart or liver failure the medicine NEO BOROCILLINA GOLA DOLORE must be used with caution. It is recommended not to associate the medicine with the NSAIDs. The use, especially if prolonged, of the product can give rise to phenomena of local sensitization or irritation; in such cases it is necessary to stop the treatment and consult the doctor to establish, if necessary, suitable therapy. Do not use for protracted treatments. After a short period of treatment without appreciable results consult your doctor. NEO BOROCILLINE GOLL NEO BOROCILLINA GOLA DOLORE oral mucosa spray (all presentations) contain: - 960 mg of ethanol for 10 ml of collutory. It can cause burning sensation on damaged skin. - hydrogenated polyoxidate castor oil that can cause reactions on the localized skin. - benzoate paraidrosis that can cause allergic reactions (also delayed). NEO BOROCILLINA GOLA DOLORE 0.25% oral mucosa spray taste orange and honey and NEO BOROCILLINA GOLA DOLORE 0.25% lemon and honey taste oral mucosa spray also contain the yellow coloring sunset (E110), which can cause allergic reactions.NEO BOROCILLINA GOLA DOLORE 8.75 mg tablets (all presentations) contains isomalto: patients suffering from rare hereditary problems of fructose intolerance, should not take this medicine.

Interactions

In any case, please inform your doctor if you take other medications. As demonstrated in some clinical studies, flurbiprofen may occasionally reduce the diuretic activity of furosemide. In addition, flurbiprofen may occasionally interfere with the action of anticoagulant drugs. No flurbiprofen interaction with digoxin, tolbutamide and antacids was demonstrated.

Effects

The use of NEO BOROCILLINA GOLA DOLORE, especially if prolonged, can give rise to phenomena of sensitization or local irritation; in such cases it is necessary to stop the treatment and to establish, if necessary, suitable therapy. The following undesirable effects were reported, particularly after the administration of higher doses by systemic means: Emolinfopoietic system pathologies Trombocytopenia, aplastic anemia and agranulocytosis. Immune system disorders Anaphylaxis, angioedema, allergic reaction. Diseases of the nervous system Capogiri, cerebrovascular accidents, visual disorders, optic neuritis, migraine, paresthesia, depression, confusion, hallucination, dizziness, discomfort, fatigue and drowsiness. Ear and labyrinth pathologies Tinnitus. Respiratory, chest and mediastinic pathologies Reactivity of the respiratory tract (asthma, bronchospasm and dispnea). Gastrointestinal diseases The most commonly observed adverse events are gastrointestinal. After administration of flurbiprofen have been reported: nausea, vomiting, diarrhea, flatulence, constipation, dyspepsia, abdominal pain, melena, hematitis, ulcerative stomatitis, gastrointestinal hemorrhage and exacerbation of colitis and Crohn's disease. Less frequently gastritis, peptic ulcer, drilling and ulcer hemorrhage were observed. Pathologies of skin and subcutaneous tissue Skin disorders including rash, itching, hives, porpora and very rarely bollose dermatosis (including Stevens-Johnson syndrome, Toxic Necrolysis Epidermal and Multiform Erythema). Kidney and urinary pathologies Nephrotoxicity in various forms including interstitial nephritis and nephrotic syndrome. As with other NSAIDs, rare cases of kidney failure were reported. Reporting of suspicious adverse reactions The reporting of suspicious adverse reactions occurring after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at the address https://www.aifa.gov.it/content/segnalazioni-reazioni-avverse

Overdosing

With the use of NEO BOROCILLINA GOLA DOLORE is rare for overdose situations to occur. Synonyms Overdose symptoms may include nausea, vomiting and gastrointestinal irritation. Treatment The treatment must include gastric lavender and, if necessary, correction of the sierial electrolytic framework. There is no specific antidote for flurbiprofen.

During the first and second trimester of pregnancy, flurbiprofen should not be administered if not in strictly necessary cases. The drug administered during pregnancy may delay the beginning of labor and aumerate its duration. Flurbiprofene administration is not recommended in nursing mothers.

Source: Farmadati